Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...
Hosted on MSN12mon
ResMed product recall classified as most serious by FDA (update)The products can be used with BiPAP and CPAP machines from other manufacturers, and patients using those devices should ensure that their masks are not part of the recall. ResMed (RMD) said that ...
OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...
ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...
The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with tech stocks outperforming as the holiday-shortened week got underway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback